Activiteit
-
It was a pleasure to be a part of this panel at BioCentury Inc. Grand Rounds in Cambridge to discuss the future treatment paradigm for obesity and…
It was a pleasure to be a part of this panel at BioCentury Inc. Grand Rounds in Cambridge to discuss the future treatment paradigm for obesity and…
Gemarkeerd als interessant door Eline Doornenbal
-
Great news from our Innovation Industries portfolio: the successful exit of The Akkermansia Company - Belgium acquired by Danone – a major milestone…
Great news from our Innovation Industries portfolio: the successful exit of The Akkermansia Company - Belgium acquired by Danone – a major milestone…
Gemarkeerd als interessant door Eline Doornenbal
-
Today marks my last day as Investment Manager of the FIRST fund at BGV (BioGeneration Ventures). I am very grateful for the past years in which I’ve…
Today marks my last day as Investment Manager of the FIRST fund at BGV (BioGeneration Ventures). I am very grateful for the past years in which I’ve…
Gemarkeerd als interessant door Eline Doornenbal
Ervaring
-
-
-
-
-
-
-
-
-
-
-
-
-
Opleiding
-
-
-
-
Master Thesis: “R&D productivity and disruptive innovation: an empirical analysis of the emerging biotechnology sector” (8.5/10)
-
-
-
Bachelor Thesis: “Expressing a putative squalene-hopene cyclase from Schizosaccharomyces japonicus in Saccharomyces cerevisiae” (9.0/10)
Minor in Political Sciences at Leiden University -
-
-
Publicaties
Talen
-
Dutch
Moedertaal of tweetalig
-
English
Volledige professionele vaardigheid
-
German
Beperkte werkvaardigheid
-
French
Beperkte werkvaardigheid
Meer activiteiten van Eline
-
Exciting news — I’m thrilled to share that I’ve joined daphni to support the company’s drive across Europe. daphni doesn’t follow the traditional…
Exciting news — I’m thrilled to share that I’ve joined daphni to support the company’s drive across Europe. daphni doesn’t follow the traditional…
Gemarkeerd als interessant door Eline Doornenbal
-
I'm delighted that we are taking Avidicure out of stealth with a USD50M seed round led by EQT! Our products are dual agonistic, multi-specific…
I'm delighted that we are taking Avidicure out of stealth with a USD50M seed round led by EQT! Our products are dual agonistic, multi-specific…
Gemarkeerd als interessant door Eline Doornenbal
-
Big news for European biotech: the Dutch 🇳🇱 government just released an ambitious vision to position the Netherlands as a global biotech leader by…
Big news for European biotech: the Dutch 🇳🇱 government just released an ambitious vision to position the Netherlands as a global biotech leader by…
Gemarkeerd als interessant door Eline Doornenbal
-
About to board our flight from San Francisco to Amsterdam—here are my key takeaways from GTC 2025 before I hop on: 📍”The future of AI is physical”…
About to board our flight from San Francisco to Amsterdam—here are my key takeaways from GTC 2025 before I hop on: 📍”The future of AI is physical”…
Gemarkeerd als interessant door Eline Doornenbal
-
Very excited to announce that Thuja Capital portfolio company EsoBiotec has entered into a definitive agreement to be acquired by AstraZeneca for a…
Very excited to announce that Thuja Capital portfolio company EsoBiotec has entered into a definitive agreement to be acquired by AstraZeneca for a…
Gemarkeerd als interessant door Eline Doornenbal
-
Wow. Meeting all primary and secondary endpoints in phase 2. That is the company’s biggest milestone so far. The initial years were tough, but…
Wow. Meeting all primary and secondary endpoints in phase 2. That is the company’s biggest milestone so far. The initial years were tough, but…
Gemarkeerd als interessant door Eline Doornenbal
-
Selective targeting and degradation of toxic protein aggregates remains highly challenging. Today we announce our investment in TRIMTECH Therapeutics…
Selective targeting and degradation of toxic protein aggregates remains highly challenging. Today we announce our investment in TRIMTECH Therapeutics…
Gemarkeerd als interessant door Eline Doornenbal